# Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

Study · id `cardio:ct-nct07866066` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07866066](<https://clinicaltrials.gov/study/NCT07866066>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07866066

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1300 participants.

## Technical summary

Registry record NCT07866066. Randomized; no masking; primary purpose treatment. Start 2026-10-16 (actual); primary completion 2028-09-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1300 participants (planned count; ClinicalTrials.gov record NCT07866066, source copy `cardio:ctgov-nct07866066-2026-11-05`, retrieved 2026-11-18)
- Started: 2026-10-16 (actual) (ClinicalTrials.gov record NCT07866066, source copy `cardio:ctgov-nct07866066-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2028-09-06 (anticipated) (ClinicalTrials.gov record NCT07866066, source copy `cardio:ctgov-nct07866066-2026-11-05`, retrieved 2026-11-18)
- Completion: 2028-12-05 (anticipated) (ClinicalTrials.gov record NCT07866066, source copy `cardio:ctgov-nct07866066-2026-11-05`, retrieved 2026-11-18)
- Countries: United States; Canada (ClinicalTrials.gov record NCT07866066, source copy `cardio:ctgov-nct07866066-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07866066-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
- Acronym: MARITIME-T2D-3
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Maridebart cafraglutide
- Intervention (Drug): Semaglutide
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 5405436d803879aef1a11267fbf14f397cc7b6de9b9db7c3bfb3ca572b738ca7
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
